Neurocrine Biosciences reported $67M in EBITDA for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agios Pharmaceuticals AGIO:US $ -102.62M 13.68M
Aptinyx Inc APTX:US $ -19279000 207K
Cytokinetics CYTK:US $ -76.52M 58.35M
Enanta Pharmaceuticals ENTA:US $ -33.02M 3.4M
Nektar Therapeutics NKTR:US $ -109.47M 0.5M
Teva Pharmaceutical TEVA:IT 1.29B 151M
Xoma XOMA:US $ -2063000 32.43M